New drug combo shows promise for rare liver disease

NCT ID NCT06174402

First seen Jan 11, 2026 · Last updated May 02, 2026 · Updated 9 times

Summary

This study tests whether adding fenofibrate to the standard treatment (ursodeoxycholic acid) can improve liver health in people with primary biliary cholangitis (PBC), a chronic liver disease. About 184 adults aged 18-75 with PBC will take the combination and be monitored for changes in liver enzyme levels and itching symptoms. The goal is to see if the combination works better than standard care alone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY BILIARY CHOLANGITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China

  • Nanjing Drum Tower Hospital

    Nanjing, Jiangsu, China

  • Nanjing Second Hospital

    Nanjing, Jiangsu, China

  • Peking Union Medical College Hospital

    Beijing, China

  • Shengjing Hospital Affiliated to China Medical University

    Shenyang, Liaoning, China

  • Sun Yat-sen Memorial Hospital

    Guangzhou, Guangdong, China

  • The Second Affiliated Hospital of Kunming Medical University

    Kunming, Yunnan, China

  • The second hospital of Lanzhou University

    Lanzhou, Gansu, China

  • Xijing Hospital

    Xi'an, Shaanxi, China

  • Yan'an University Affiliated Hospital

    Yan’an, Shanxxi, China

Conditions

Explore the condition pages connected to this study.